Biopharm: Foundations similar to that funding Thorpe and Brekke are common funding agents for scholars of all stripes in almost all universities. Brekke has for some time been an up-and-coming star in the UTSW stable of prime movers more importantly for conspiring with Affitec in developing PPHM's "2C3". Its side effect profile is much better than Avastin, and 2C3 is more specific than Avastin. PPHM's "Better-than-Avastin" 2C3 is an anti-angiogenesis PPHM pipeliner partnered with Affitec, and is undergoing human trials in Russia, a state-of-the-art MAB that could easily replace Avastin. Like Cotara in China, 2C3 outcomes have disappeared behind the iron curtain, much like Cotara for Glioblastoma Multiforme has fallen off the radar screen. And we haven't even mentioned PPHM's showboat MAB, Bavituximab. As a physician, I went on record here and on another board that I would prescribe either or both (together) in a heartbeat for lung cancer. So who is in chargein this country? Not patients or doctors. Not the FDA. Could it be Wall Street? Madison Avenue? Apple? The Media? Gov'ment? Who is it out there that moves good therapeutics to the treatment table? Its MONEY people.Anyone out there try to get Bavituximab on a "compassionate use" basis? I would love to hear from youif you or a friend has tried to get Bavi. Congress was supposed to have made made it easier with some bill or other they passed, remember? Now Anyone should be able to request Bavi and get it. My impression is part of the problem can be the doctors (and patients). Example: The oncologist who apparently does bit want to be bothered by the paperwork it takes to get Bavi for an informed patient. And they do not get paid for writing letters to government agencies, or making telephone calls. It's easier to get illegal drugs than Bavi. Pot? No problem. I encouraged a dying friend to talk to his oncologist about Bavi, and the oncologist wouldn't hear of it. "I believe it is not approved for your cancer", he said. Same with another cancer patient, a family member. I ask again, who is in charge here? Not our CEO, SK. He's a physician, and he's convinced Bavi "works". Believe me, SK would LOVE to move this thing along. Granted, those invested heavily in a concept usually are more convinced of its efficacy. But let's face it, entrepreneurial greed is what controls access to almost all medicinals. And as you've noticed with the "socialization" of medicine, doctors are not the best entrepreneurs. Worse, doctors don't even get a pass in the greed blame-game. MAB appearance on the treatment scene was greeted with exuberant skepticism by almost all branches of the cancer treatment bureacracy, and obtaining a foothold on the cancer treatment table was enormously costly for Roche, Genentech, and ImClone. So why the stock price if Bavi- appears to be the best out there for 2ndline Nsclc? Today, it's "Ayer is getting out". Ridiculous. What should that have to do with Cotara sitting idle, and Bavi in a statistical stew. 1st-line NSCLC results remain unexplainably shrouded in mysterious obscurity. The inventor dies. The trials are subverted. Come on!I thought we were trying to cure cancer. This is like living a novel...
AI
